Navigation Links
12 Month Follow-Up Data for Isotope-Free Breast IORT Presented at ASBS Meeting

LAS VEGAS, April 28 /PRNewswire/ -- Utilization of the FDA cleared Axxent® Electronic Brachytherapy, eBx™, System to deliver intraoperative radiation therapy (IORT) is growing as clinical experience demonstrates the isotope-free cancer treatment platform is a patient and physician friendly alternative.  Xoft will showcase a variety of IORT oncology applications at the 11th Annual Meeting of the American Society of Breast Surgeons here, April 28-May 2, 2010.

In the study, "Twelve-Month Follow-Up Results of a Trial Utilizing Xoft Axxent Electronic Brachytherapy to Deliver Intraoperative Radiation Therapy for the Early Stage Breast Cancer," researchers enrolled 11 patients in an IRB approved IORT treatment protocol and reported oncologic, cosmetic and mammographic outcomes at one year post-IORT.  The 12-month results suggest that IORT utilizing Xoft's Electronic Brachytherapy is emerging as a novel, patient and physician friendly alternative to Whole Radiation Therapy (WBRT) as well as APBI in a selected group of patients with early breast cancer.  This work is presented in ASBS Poster #66 by Olga Ivanov, M.D., breast surgeon and medical director for Little Company of Mary's Comprehensive Breast Health Center.

"When compared to other radiation techniques, IORT is emerging as a feasible, well-tolerated alternative to post-surgical APBI and whole breast radiation therapy. In this trial, eBx was utilized for the first time to successfully deliver 20 Gy of radiation intra-operatively to 11 patients. At a mean follow-up of 12 months, overall results are extremely encouraging with excellent scores achieved in cosmesis and patient satisfaction.  While long-term follow-up will continue, no recurrences have been observed to date," said Dr. Ivanov.

"In addition to the potential clinical benefits, from a patient's perspective the nominal extra time spent by the radiation oncologist and surgeon in the OR will negate the often difficult logistics of WBRT or APBI," added Dr. Ivanov.  "The use of IORT may also obviate the need for mastectomy in patients who cannot travel to a radiation treatment center for therapy where it has been shown that an increase in travel distance to a radiation facility decreases the chances of a woman receiving treatment.  In one study only 51% of women completed prescribed therapy if they lived more than 75 miles from the radiation facility."

IORT is a radiation therapy technique where a concentrated dose of radiation is delivered to a cancerous tumor site during surgery after the tumor is removed.  Because the target and normal tissues can be clearly identified during surgery, IORT may increase targeting accuracy, thereby increasing dose to the target and reducing dose to critical structures. For breast IORT, the shorter treatment time is generally more convenient for patients than the seven-week course of external beam-therapy, and may increase patient compliance.

The Xoft eBx System uses a miniaturized X-ray source instead of a radioactive isotope to deliver radiation to the breast from within a balloon catheter. The low energy and rapid dose fall-off of the electronic source permit treatment in typical operating rooms, with minimal shielding required. Lightweight and mobile, the system can be moved easily between multiple ORs.

Available for treatment of early stage breast cancer, endometrial cancer, and skin cancer, the Axxent eBx System is also FDA-cleared for IORT (intra-operative radiation therapy). As a platform technology, the Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Utilizing a proprietary miniaturized X-ray source and robotic controller, the system can be used to deliver radiation in minimally shielded therapeutic settings. Treatment can be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during treatment delivery which minimizes patient anxiety.

"We are very pleased with the strong interest in and growing adoption of multi-disciplinary approaches for use of Electronic Brachytherapy to deliver IORT for breast and other cancers," said Michael Klein, president and CEO of Xoft. "We are encouraged that studies reinforce the clinical value of IORT applications for eBx, and strongly believe that providing a safe and portable method to deliver treatment to the lumpectomy cavity as soon as the tumor is removed and before any remaining cells have a chance to reproduce, is extremely important to improving patient care."

About Xoft, Inc.

Xoft develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments. The Axxent® treatment platform provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healthy tissue and without the complex handling, resource logistics and costs associated with using radioactive isotopes. Xoft aligns with the Nuclear Regulatory Commission's (NRC) directive to seek alternatives for radioactive medical isotopes. Commercially available for treatment of early stage breast cancer, skin cancer and endometrial cancer indications, the Axxent Electronic Brachytherapy System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. For information, visit

Axxent is a registered trademark and eBx is a trademark of Xoft, Inc.

SOURCE Xoft, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioGenics to be Spotlighted in Three Publications During Month of April
2. Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer
3. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
4. Colon Cancer Awareness Month Begins With the News That President Obama Selected Virtual Colonoscopy For His Colon Cancer Screening
5. One Month After Haitis Devastating Earthquake, Relief Efforts Robust but Rains Bring More Misery
6. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009
7. Launch of Ipsens Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer
8. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
9. MPR (Monthly Prescribing Reference) Drug Database Available as a Free Application for the iPhone and iPod touch
10. February is National Childrens Dental Health Month -- Remember to Brush and Floss Every Day is the Message -- Kids With Braces Need to be Extra Vigilant
11. Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey
Post Your Comments:
(Date:12/1/2015)... India , December 1, 2015 ... market research report "Immunotherapy Drugs Market by Type of Drug ... Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast ... is poised to reach USD 73,529.2 Million by 2020 from ... from 2015 to 2020. Browse 37 ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
(Date:12/1/2015)... 2015 During the recent 2015 Transcatheter ... Francisco, CA , Medinol Ltd. continued to ... During a satellite symposium, "The BioNIR eDES: The ... Restenosis", a renowned physician panel discussed the key ... Coronary Stent System and the Medinol eDES Coronary ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare ... IT Healthcare was recognized as a finalist in the category of Digital Solutions ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... 01, 2015 , ... PYA’s latest white paper, “ PYA ... main “pain point” for merging or aligning healthcare provider organizations—when mergers and other ... This quick-read guidance suggests that failing to recognize the power of an ...
(Date:12/1/2015)... ... 2015 , ... PartnerTech , a leader in high-tech ... 2008. Gary Bruce, President of PartnerTech North America, currently serves as Director for ... of time in Sweden since joining PartnerTech based in Malmo, Sweden. He has ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker of ... to date. , The order will be from the China Disabled Persons’ Federation, ... System is an effective solution for children and adults suffering from severe and ...
Breaking Medicine News(10 mins):